Progyny Stock Forecast, Price & News

-0.65 (-1.01 %)
(As of 06/15/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume714,135 shs
Average Volume882,336 shs
Market Capitalization$5.65 billion
P/E Ratio111.97
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PGNY News and Ratings via Email

Sign-up to receive the latest news and ratings for Progyny and its competitors with MarketBeat's FREE daily newsletter.

Progyny logo

About Progyny

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.


Progyny (PGNY) vs. Its Peers Financial Analysis
Progyny (PGNY) vs. Its Peers Financial Analysis
June 15, 2021 |
Progyny (PGNY) & Its Peers Head-To-Head Comparison
Progyny (PGNY) & Its Peers Head-To-Head Comparison
June 14, 2021 |
Comparing Progyny (PGNY) & Its Peers
Comparing Progyny (PGNY) & Its Peers
June 13, 2021 |
Reviewing Progyny (PGNY) & Its Peers
Reviewing Progyny (PGNY) & Its Peers
June 12, 2021 |
Contrasting Progyny (PGNY) and The Competition
Contrasting Progyny (PGNY) and The Competition
June 12, 2021 |
Head to Head Analysis: Progyny (PGNY) versus Its Rivals
Head to Head Analysis: Progyny (PGNY) versus Its Rivals
June 12, 2021 |
Progyny (PGNY) versus The Competition Head-To-Head Survey
Progyny (PGNY) versus The Competition Head-To-Head Survey
June 11, 2021 |
Progyny (NASDAQ:PGNY) Sees Strong Trading Volume
Progyny (NASDAQ:PGNY) Sees Strong Trading Volume
June 11, 2021 |
See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.67 out of 5 stars

Medical Sector

357th out of 2,100 stocks

Miscellaneous Health & Allied Services, Not Elsewhere Classified Industry

7th out of 29 stocks

Analyst Opinion: 1.4Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Progyny (NASDAQ:PGNY) Frequently Asked Questions

Is Progyny a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Progyny in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Progyny stock.
View analyst ratings for Progyny
or view top-rated stocks.

What stocks does MarketBeat like better than Progyny?

Wall Street analysts have given Progyny a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Progyny wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Progyny's next earnings date?

Progyny is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Progyny

How were Progyny's earnings last quarter?

Progyny, Inc. (NASDAQ:PGNY) posted its quarterly earnings data on Thursday, May, 6th. The company reported $0.15 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.08 by $0.07. The company earned $122.13 million during the quarter, compared to analyst estimates of $121.27 million. Progyny had a net margin of 14.97% and a trailing twelve-month return on equity of 17.31%. The business's quarterly revenue was up 50.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.04 EPS.
View Progyny's earnings history

How has Progyny's stock price been impacted by Coronavirus (COVID-19)?

Progyny's stock was trading at $22.31 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PGNY shares have increased by 186.1% and is now trading at $63.82.
View which stocks have been most impacted by COVID-19

What guidance has Progyny issued on next quarter's earnings?

Progyny updated its FY 2021 earnings guidance on Thursday, May, 27th. The company provided earnings per share guidance of 0.330-0.410 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.340. The company issued revenue guidance of $520 million-$540 million, compared to the consensus revenue estimate of $535.20 million.

What price target have analysts set for PGNY?

6 brokers have issued twelve-month price objectives for Progyny's stock. Their forecasts range from $32.00 to $64.00. On average, they expect Progyny's share price to reach $43.40 in the next twelve months. This suggests that the stock has a possible downside of 32.0%.
View analysts' price targets for Progyny
or view top-rated stocks among Wall Street analysts.

Who are Progyny's key executives?

Progyny's management team includes the following people:
  • Mr. David J. Schlanger, CEO & Director (Age 62, Pay $987.31k)
  • Mr. Peter Anevski, Pres & COO (Age 54, Pay $909.86k)
  • Mr. Mark S. Livingston, Chief Financial Officer (Age 55, Pay $857.01k)
  • Ms. Jennifer Bealer, Exec. VP, Gen. Counsel & Sec. (Age 40, Pay $499.12k)
  • Mr. James Hart, VP of Investor Relations
  • Ms. Risa Fisher, Exec. VP of Marketing & Communication
  • Ms. Cassandra Pratt, Sr. VP of People
  • Mr. Michael Sturmer, Exec. VP, Chief Growth & Strategy officer

What is David Schlanger's approval rating as Progyny's CEO?

25 employees have rated Progyny CEO David Schlanger on David Schlanger has an approval rating of 89% among Progyny's employees.

Who are some of Progyny's key competitors?

What other stocks do shareholders of Progyny own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Progyny investors own include NVIDIA (NVDA), Alibaba Group (BABA), (CRM), Marvell Technology (MRVL), Alteryx (AYX), Micron Technology (MU), AbbVie (ABBV), The Home Depot (HD), Honeywell International (HON) and Advanced Micro Devices (AMD).

When did Progyny IPO?

(PGNY) raised $150 million in an initial public offering on Friday, October 25th 2019. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers.

What is Progyny's stock symbol?

Progyny trades on the NASDAQ under the ticker symbol "PGNY."

Who are Progyny's major shareholders?

Progyny's stock is owned by many different retail and institutional investors. Top institutional investors include KPCB XIII Associates LLC (9.37%), Fred Alger Management LLC (5.27%), Clearbridge Investments LLC (2.85%), BlackRock Inc. (2.56%), JPMorgan Chase & Co. (2.54%) and Orbimed Advisors LLC (2.17%). Company insiders that own Progyny stock include Beth C Seidenberg, David J Schlanger, David J Schlanger, Group Holdings (Sbs) Advis Tpg, Jennifer Bealer, Karin Ajmani, Lisa Greenbaum, Mark S Livingston, Norman Payson, Perkins Caufield & Bye Kleiner, Peter Anevski and Plc Glaxosmithkline.
View institutional ownership trends for Progyny

Which institutional investors are selling Progyny stock?

PGNY stock was sold by a variety of institutional investors in the last quarter, including KPCB XIII Associates LLC, Woodline Partners LP, General Equity Holdings LP, Pier Capital LLC, Rothschild & Co. Asset Management US Inc., Owls Nest Partners IA LLC, Sei Investments Co., and First Sabrepoint Capital Management LP. Company insiders that have sold Progyny company stock in the last year include Beth C Seidenberg, David J Schlanger, Group Holdings (Sbs) Advis Tpg, Jennifer Bealer, Lisa Greenbaum, Mark S Livingston, Norman Payson, Perkins Caufield & Bye Kleiner, and Peter Anevski.
View insider buying and selling activity for Progyny
or view top insider-selling stocks.

Which institutional investors are buying Progyny stock?

PGNY stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Waddell & Reed Financial Inc., Jennison Associates LLC, Orbimed Advisors LLC, Polen Capital Management LLC, Neuberger Berman Group LLC, Fred Alger Management LLC, and Schroder Investment Management Group.
View insider buying and selling activity for Progyny
or or view top insider-buying stocks.

How do I buy shares of Progyny?

Shares of PGNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Progyny's stock price today?

One share of PGNY stock can currently be purchased for approximately $63.82.

How much money does Progyny make?

Progyny has a market capitalization of $5.65 billion and generates $344.86 million in revenue each year. The company earns $46.46 million in net income (profit) each year or $0.18 on an earnings per share basis.

How many employees does Progyny have?

Progyny employs 210 workers across the globe.

What is Progyny's official website?

The official website for Progyny is

Where are Progyny's headquarters?

Progyny is headquartered at 1359 BROADWAY, NEW YORK NY, 10018.

How can I contact Progyny?

Progyny's mailing address is 1359 BROADWAY, NEW YORK NY, 10018. The company can be reached via phone at 212-888-3124 or via email at [email protected]

This page was last updated on 6/15/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.